Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vacci

[News]

Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, hascompleted an interim analysis of its first two clinical studies withMVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients. The first study, performed in the US, is evaluating MVA-BN(R)-HER2treatment following chemotherapy and Herceptin(R) treatment.

More... (http://www.medicalnewstoday.com/articles/112030.php)